Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines

Pancreatology

Volumn 3, Issue 5, 2003, Pages 367-374

  Whitehouse, P A ^a   Cooper, A J ^a   Johnson, C D ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Pancreatic adenocarcinoma; Linolenic acid

Indexed keywords

CYTOTOXIC AGENT; FLUOROURACIL; GAMMA LINOLENIC ACID; GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOMASS; CANCER CELL CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL TEST; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0242460554     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000073651     Document Type: Article

References (39)

1. Rosewicz S, Wiedenmann B: Pancreatic carcinoma. Lancet 1997;349:485-489.
2. Ridwelski K, Meyer F: Current options for palliative treatment in patients with pancreatic cancer. Dig Dis 2001;19:63-75.
3. Mallinson CN, Rake MO, Cocking JB, Fox CA, Cwynarski MT, Diffey BL, Jackson GA, Han-ley J, Wass VJ: Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre trial. BMJ 1980;281: 1589-1591.
4. Palmer KR, Kerr M, Knowles G, Culli A, Carter DC, Leonard RCF: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-885.
5. Glimelius B, Hoffman K, Sjoden PO, Jacobs-son G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
6. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
7. Falconer JS, Ross JA, Fearon KCH, Hawkins RA, O'Riordain MG, Carter DC: Effect of ei-cosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 1994;69:826-832.
8. Ravichandran D, Cooper A, Johnson CD: Effect of lithium γ-linolenate on the growth of experimental human pancreatic carcinoma. Br J Surg 1998;85:1201-1205.
9. Ravichandran D, Cooper A, Johnson CD: Growth inhibitory effect of lithiumγ-linolen-ate on pancreatic cancer cell lines: The influence of albumin and iron. Eur J Cancer 1998;34:188-192.
10. Seegars JC, de Kock M, Lottering ML, Grobler CJS, van Papendorp DH, Habbersett R, Leh-nert BE: Effects ofγ-linolenic acid and arachi-donic acid on cell cycle progression and apop-tosis induction in normal and transformed cells. Prostaglandins Leukot Essent Fatty Acids 1997;56:271-280.
11. Jiang WG, Hiscox S, Hallett MB, Scott C, Hor-robin DF, Puntis MCA: Inhibition of hepato-cyte growth factor-induced motility and in vitro invasion of human colon cancer cells by γ-linolenic acid. Br J Cancer 1995;71:744-752.
12. Solomon LZ, Jennings AM, Hayes MC, Bass PS, Birch BR, Cooper AJ: Isγ-linolenic acid an effective intravesical agent for superficial bladder cancer? In vitro cytotoxicity and in vivo tolerance studies. Urol Res 1998;26:11-15.
13. Naidu MRC, Das UN, Kishan A: Intratumoral γ-linoleic acid therapy of human gliomas. Pros-taglandins Leukot Essent Fatty Acids 1992;45: 181-184.
14. Das UN, Prasad VVSK, Raia Reddy D: Local application ofγ-linolenic acid in the treatment of human gliomas. Cancer Lett 1995;94:147-155.
15. Begin ME, Ells G, Horrobin DF: Polyunsatu-rated fatty acid-induced cytotoxicity against tumour cells and its relationship to lipid peroxidation. J Natl Cancer Inst 1988;80:188-194.
16. Weber JM, Sircar S, Begin M: Greater sensitivity of human multidrug-resistant (mdr) cancer cells to polyunsaturated fatty acids than their non-mdr counterparts. J Natl Cancer Inst 1994;86:638-639.
17. Plumb JA, Luo W, Kerr DJ: Effect of polyun-saturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cis-platin or doxorubicin. Br J Cancer 1993;67: 728-733.
18. Sircar S, Cai F, Begin ME, Weber GM: Transformation renders mdr cells more sensitive to polyunsaturated fatty acids. Anticancer Res 1990;10:1783-1786.
19. Alley MC, Scudiero D, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR: Feasibility of drug screening with panels of human cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
20. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
21. Liehr RM, Melnykovych G, Solomon TE: Growth effects of regulatory peptides on human pancreatic cancer cell lines Panc-1 and MIA PaCa-2. Gastroenterology 1990;98:1666-1674.
22. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;4(suppl 11):72-79.
23. Bergman AM, Ruiz van Haperen VW, Veer-man G, Kuiper CM, Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996 2:521-530.
24. Budman DR, Calabro A, Kreis W: In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anti-cancer Drugs 1998 9:697-702.
25. Van Moorsel CJ, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJ, Vermorken JB, Postmus PE, Peters GJ: Combination chemotherapy studies with gemcitabine and etopo-side in non-small cell lung and ovarian cancer cell lines. Biochem Pharmacol 1999;57:407-415.
26. Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC, Fearon KCH: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996;12(suppl 1):27-30.
27. Wigmore SJ, Fearon KCH, Maingay JP, Ross JA: Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997;92:215-221.
28. Lai PBS, Ross JA, Fearon KCH, Anderson JD, Carter DC: Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Br J Cancer 1995;74:1375-1383.
29. Calviello G, Palozza P, Piccioni E, Maggiano N, Frattucci A, Franceschelli P, Bartoli GM: Dietary supplementation with eicosapentaeno-ic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: Effects on proliferation and apoptosis. Int J Cancer 1998;75:699-705.
30. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MCA: Regulation of the expression of E-cadherins on human cancer cells byγ-linolenic acid. Cancer Res 1995;55: 5043-5048.
31. Booyens J, Koenig L: The effect of dietary supplementation with γ-linolenic acid on the growth of induced tumours in rats. S Afr Med J 1984;65:660-661.
32. Van der Merwe CF, Booyens J, Joubert HF, van der Merwe CA: The effect ofγ-linolenic acid, an in vitro cytostatic substance contained in evening primrose oil, on primary liver cancer. A double-blind placebo-controlled trial. Prostaglandins Leukot Essent Fatty Acids 1990;40:199-202.
33. Fearon KCH, Falconer JS, Ross JA, Carter DC, Hunter JO, Reynolds PD, Tuffnell Q: An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium γ-linolenate. Anticancer Res 1996;16:867-748.
34. Johnson CD, Puntis M, Davidson N, Todd S, Bryce R: A randomised dose-finding phase III study of lithium gamolenate (LiGLA) in patients with advanced pancreatic adenocarcino-ma. Br J Surg 2001;88:662-668.
35. Spector AA, Fletcher JE: Transport of fatty acid in the circulation; in Dietschy JM, Gotto AM Jr, Ontko JA (eds): Disturbances in Lipid and Lipoprotein Metabolism. Bethesda, American Physiological Society, 1978, pp 229-249.
36. Hostmark AT, Lystad E: Growth inhibition of human hepatoma cells (HepG2) by polyunsatu-rated fatty acids. Protection by albumin and vitamin E. Acta Physiol Scand 1992;144:83-88.
37. Shi X, Liu S, Kleeff J, Friess H, Büchler MW: Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002;62:354-362.
38. Kornmann M, Butzer U, Blatter J, Beger HG, Link KH: Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur J Surg Oncol 2000;26:583-587.
39. Miura S, Yoshimura Y, Endo M, Satoh H, Machida H, Sasaki T: Comparison of 1-(2-de-oxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cy-tosine with gemcitabine in its antitumour activity. Cancer Lett 1999;144:177-182.